ImmuCell

ImmuCell FCF Growth

The Year-over-Year Free Cash Flow Growth of ImmuCell (ICCC) as of Oct 27, 2026 is 1,236.00 %. In the previous year, Year-over-Year Free Cash Flow Growth was 98.36 % — a change of 1,156.63% (higher).

FCF Growth

1,236.00 %

YoY

1,156.63%

Last updated:

Year-over-Year Free Cash Flow Growth of ImmuCell is 2025 1,236.00 % . Year-over-Year Free Cash Flow Growth of ImmuCell was 2024 98.36 % . It decreases by 1,156.63% higher compared to the previous year.

The ImmuCell FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
85.51 USD
Jan 1, 2019
51.82 USD
Jan 1, 2020
-138.09 USD
Jan 1, 2021
39.99 USD
Jan 1, 2022
-233.59 USD
Jan 1, 2023
-18.98 USD
Jan 1, 2024
98.36 USD
Jan 1, 2025
1,236.00 USD
The ImmuCell FCF Growth history
YEARFCF GrowthYoY
1,236.00 %+1,156.63%
98.36 %-618.18%
-18.98 %-91.87%
-233.59 %-684.13%
39.99 %-128.96%
-138.09 %-366.49%
51.82 %-39.40%
85.51 %-126.38%
-324.12 %-85.66%
-2,259.80 %-2,070.51%
114.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Year-over-Year Free Cash Flow Growth of ImmuCell is 1,236.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth ImmuCell since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's ImmuCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ImmuCell

All Key Metrics — ImmuCell